Browsing by Author "Ersoy C."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)
    (Elsevier Ireland Ltd, 2018) Sonmez A.; Haymana C.; Bayram F.; Salman S.; Dizdar O.S.; Gurkan E.; Kargili Carlıoglu A.; Barcin C.; Sabuncu T.; Satman I.; Guldiken S.; Ayturk S.; Yilmaz M.; Asik M.; Dinccag N.; Cakmak R.; Turker F.; Idiz C.; Hacisahinogullari H.; Bagdemir E.; Yildiz B.; Yumuk V.D.; Haliloglu O.; Sancak S.; Ozsari L.; Cagiltay E.; Deyneli O.; Imre E.; Gonen S.; Boysan S.N.; Altuntas Y.; Ozturk F.Y.; Mert M.; Piskinpasa H.; Aydin H.; Imamoglu S.; Ersoy C.; Gul O.O.; Kucuksarac Kiyici S.; Cetinarslan B.; Selek A.; Dogru T.; Kirik A.; Kebapci N.; Efe B.; Kaya A.; Cordan I.; Baldane S.; Kirac C.O.; Demirci I.; Capa Z.; Cesur M.; Yetkin I.; Corapcioglu D.; Canlar S.; Bulent Yildiz O.; Sendur S.N.; Cakir B.; Ozdemir D.; Corakci A.; Kutlu M.; Bascil Tutuncu N.; Bozkus Y.; Cakal E.; Demirbas B.; Ertek S.; Altay M.; Dagdeviren M.; Abedi A.H.; Cetinkalp S.; Ozisik H.; Oruk G.G.; Yener S.; Saydam B.O.; Guney E.; Unubol M.; Yaylali G.F.; Topsakal S.; Hekimsoy Z.; Akbaba G.; Aslan I.; Balci M.K.; Dalkiran S.; Akbay E.; Gul K.; Agbaht K.; Yilmaz M.O.; Bozkirli E.; Tetiker B.T.; Cetinkaya Altuntas S.; Atmaca A.; Durmuş E.T.; Mete T.; Kutluturk F.; Kucukler F.K.; Dikbas O.; Akin S.; Nuhoglu I.; Ersoz H.O.; Bayraktaroglu T.; Sisman P.; Sahin I.; Cetin S.; Capoglu I.; Akbas E.M.; Ucler R.; Eren M.A.; Tuzcu A.K.; Pekkolay Z.; Ozkaya M.; Araz M.
    Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus. Methods: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c < 7%, home arterial blood pressure (ABP) < 135/85 mmHg, or LDL-C < 100 mg/dL. Achieving all parameters indicated triple metabolic control. Results: HbA1c levels of patients (n = 5211) were 8.6 ± 1.9% (71 ± 22 mmol/mol) and 7.7 ± 1.7% (61 ± 19 mmol/mol), in Type 1 and Type 2 diabetes, respectively. Glycemic control was achieved in 15.3% and 40.2%, and triple metabolic control was achieved in 5.5% and 10.1%, respectively. Only 1.5% of patients met all the criteria of being non-obese, non-smoker, exercising, and under triple metabolic control. Low education level was a significant predictor of poor glycemic control in both groups. Conclusions: Few patients with Type 2, and even fewer with Type 1 diabetes have optimal metabolic control in Turkey. TEMD study will provide evidence-based information to policy makers to focus more on the quality and sustainability of diabetes care in order to reduce the national burden of the disease. © 2018 Elsevier B.V.
  • No Thumbnail Available
    Item
    Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study)
    (BioMed Central Ltd, 2020) Bayram F.; Sonmez A.; Haymana C.; Sabuncu T.; Dizdar O.S.; Gurkan E.; Carlioglu A.K.; Agbaht K.; Ozdemir D.; Demirci I.; Barcin C.; Salman S.; Tetiker T.; Balci M.K.; Kebapci N.; Ersoy C.; Yumuk V.; Toth P.P.; Satman I.; Guldiken S.; Ayturk S.; Yilmaz M.; Asik M.; Dinccag N.; Cakmak R.; Turker F.; Idiz C.; Hacisahinogullari H.; Bagdemir E.; Yildiz B.; Haliloglu O.; Sancak S.; Ozsari L.; Cagiltay E.; Deyneli O.; Imre E.; Gonen S.; Boysan S.N.; Altuntas Y.; Ozturk F.Y.; Mert M.; Piskinpasa H.; Aydin H.; Imamoglu S.; Gul O.O.; Kiyici S.K.; Cetinarslan B.; Selek A.; Dogru T.; Kirik A.; Efe B.; Kaya A.; Cordan I.; Baldane S.; Kirac C.O.; Capa Z.; Cesur M.; Yetkin I.; Corapcioglu D.; Canlar S.; Yildiz O.B.; Sendur S.N.; Cakir B.; Corakci A.; Kutlu M.; Tutuncu N.B.; Bozkus Y.; Cakal E.; Demirbas B.; Ertek S.; Altay M.; Dagdeviren M.; Abedi A.H.; Cetinkalp S.; Ozisik H.; Oruk G.G.; Yener S.; Saydam B.O.; Guney E.; Unubol M.; Yaylali G.F.; Topsakal S.; Hekimsoy Z.; Akbaba G.; Aslan I.; Dalkiran S.; Akbay E.; Gul K.; Yilmaz M.O.; Bozkirli E.; Altuntas S.C.; Atmaca A.; Durmuş E.T.; Mete T.; Kutluturk F.; Kucukler F.K.; Dikbas O.; Akin S.; Nuhoglu I.; Ersoz H.O.; Bayraktaroglu T.; Sisman P.; Sahin I.; Cetin S.; Capoglu I.; Akbas E.M.; Ucler R.; Eren M.A.; Tuzcu A.K.; Pekkolay Z.; Ozkaya M.; Araz M.
    Background: Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians’ attitudes on the treatment of diabetic dyslipidemia were also examined. Methods: A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. Results: A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 ± 1.74% and 10.9 ± 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59–0.83). Conclusions: Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM. © 2020, The Author(s).
  • No Thumbnail Available
    Item
    Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients
    (John Wiley and Sons Inc, 2022) Yavuz D.G.; Yazan C.D.; Hekimsoy Z.; Aydin K.; Gokkaya N.; Ersoy C.; Akalın A.; Topaloglu O.; Aydogan B.I.; Dilekci E.N.A.; Alphan Uc Z.; Cansu G.B.; Ozsari L.; Iyidir O.T.; Olgun M.E.; Keskin L.; Mert M.; Can B.; Gungor K.; Galip T.; Cantürk Z.; Elbuken G.; Pekkolay Z.; Kutbay N.O.; Yorulmaz G.; Kalkan A.T.; Unsal Y.A.; Yay A.; Karagun B.; Bozkur E.
    Objective: Thyroid-stimulating hormone (TSH) suppression treatment can induce signs and symptoms of hyperthyroidism and hypothyroidism due to inappropriate treatment or poor compliance to the treatment. The current study aimed to investigate TSH levels, frequency of being on target TSH, adherence to levothyroxine (LT4) suppression treatment in differentiated thyroid cancer (DTC) patients after surgery in a multicentric setting. Design and Patients: This multicentric cross-sectional study was conducted at 21 medical centres from 12 cities in Turkey. DTC patients followed at least one year in the same center included in the study. Clinical data, serum TSH, free thyroxine (FT4), thyroglobulin (Tg) and anti-Tg levels were recorded during the most recent visit. Body mass index, systolic and diastolic blood pressures, pulse rate were measured. LT4 doses were recorded and doses per kilogram of bodyweight were calculated. Pill ingestion habits recorded and adherence to the therapy were evaluated using the Morisky Medication Adherence Scale and categorized as good, moderate or poor compliant based on their scores. Risk stratification forpredicting the disease persistance and/or reccurence was assessed using the American Joint Committee on Cancer-7th edition thyroid cancer staging calculator. TSH serum concentrations were classified as severe suppression (TSH < 0.01 mU/L), moderate suppression (TSH: 0.01–0.1 mU/L), mild suppression (TSHL 0.1–0.5 mU/L), euthyroid (TSH: 0.5–4 mU/L) and hypothyroid (TSH > 4 mU/L). TSH levels can also be classified as on being on target, under the target, or beyond over the target, according to the American Thyroid Association recommendations. Results: A group of 1125 patients (F/M: 941/184, 50.7 ± 11.7 years) were included in the study. The mean LT4 daily dosage was 132.4 ± 39.6 mcg/day. TSH levels showed severe suppression in 99 (%8.8) patients, moderate suppression in 277 (%24.6) patients and mild suppression in 315 (%28) patients and euthyroid range in 332 (%29.5) patients and hypothyroid range in 97 (8.6%). TSH levels were in target in 29.2% of the patients 20.4% of the patients were undertreated, 50.4% overtreated. The daily LT4 dose and LT4 dose/kg were significantly higher in the severe suppression group (p <.001, p <.001). According to the Morisky scale, 564 patients (50.1%) were good compliant, 368 patients (32.7%) were moderate compliant, and 193 patients (17.1%) were noncompliant. Patients with poor compliance need a higher dose of LT4 compared to the good compliance group (p <.001). TSH levels of patients with good compliance were 0.67 ± 1.96 mU/L and TSH with poor compliance was 2.74 ± 7.47 mU/L (p <.001). TSH levels were similar in patients on fixed and alternating dosages. Conclusion: In 29.2% of the DTC patients, serum TSH levels were at target levels. Remaining of the study group have TSH levels under or over treatment range, exposing the patient to medication side effects. Majorty of the study group 82.8% have good or moderate adherence to LT4 therapy. Reaching TSH targets requires simplified and applicable guidelines and following the guideline recommendations. © 2022 John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Identifying Clinical Characteristics of Hypoparathyroidism in Turkey: HIPOPARATURK-NET Study
    (Springer, 2022) Konca Degertekin C.; Gogas Yavuz D.; Pekkolay Z.; Saygili E.; Ugur K.; Or Koca A.; Unubol M.; Topaloglu O.; Aydogan B.I.; Ozdemir Kutbay N.; Hekimsoy Z.; Yilmaz N.; Balci M.K.; Tanrikulu S.; Aydogan Unsal Y.; Ersoy C.; Omma T.; Keskin M.; Yalcin M.M.; Yetkin I.; Soylu H.; Karakose M.; Yilmaz M.; Karakilic E.; Piskinpasa H.; Batman A.; Akbaba G.; Elbuken G.; Tura Bahadir C.; Kilinc F.; Bilginer M.C.; Turhan Iyidir O.; Canturk Z.; Aktas Yilmaz B.; Sayiner Z.A.; Eroglu M.
    Hypoparathyroidism is an orphan disease with ill-defined epidemiology that is subject to geographic variability. We conducted this study to assess the demographics, etiologic distribution, treatment patterns and complication frequency of patients with chronic hypoparathyroidism in Turkey. This is a retrospective, cross-sectional database study, with collaboration of 30 endocrinology centers located in 20 cities across seven geographical regions of Turkey. A total of 830 adults (mean age 49.6 ± 13.5 years; female 81.2%) with hypoparathyroidism (mean duration 9.7 ± 9.0 years) were included in the final analysis. Hypoparathyroidism was predominantly surgery-induced (n = 686, 82.6%). The insulting surgeries was carried out mostly due to benign causes in postsurgical group (SG) (n = 504, 73.5%) while patients in nonsurgical group (NSG) was most frequently classified as idiopathic (n = 103, 71.5%). The treatment was highly dependent on calcium salts (n = 771, 92.9%), calcitriol (n = 786, 94.7%) and to a lower extent cholecalciferol use (n = 635, 76.5%) while the rate of parathyroid hormone (n = 2, 0.2%) use was low. Serum calcium levels were most frequently kept in the normal range (sCa 8.5–10.5 mg/dL, n = 383, 46.1%) which might be higher than desired for this patient group. NSG had a lower mean plasma PTH concentration (6.42 ± 5.53 vs. 9.09 ± 7.08 ng/l, p < 0.0001), higher daily intake of elementary calcium (2038 ± 1214 vs. 1846 ± 1355 mg/day, p = 0.0193) and calcitriol (0.78 ± 0.39 vs. 0.69 ± 0.38 mcg/day, p = 0.0057), a higher rate of chronic renal disease (9.7% vs. 3.6%, p = 0.0017), epilepsy (6.3% vs. 1.6%, p = 0.0009), intracranial calcifications (11.8% vs. 7.3%, p < 0.0001) and cataracts (22.2% vs. 13.7%, p = 0.0096) compared to SG. In conclusion, postsurgical hypoparathyroidism is the dominant etiology of hypoparathyroidism in Turkey while the nonsurgical patients have a higher disease burden with greater need for medications and increased risk of complications than the postsurgical patients. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
  • No Thumbnail Available
    Item
    Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
    (AVES, 2024) Çetinarslan B.; Çetinkalp Ş.; Kaya A.; Ersoy C.; Kebapçı N.; Çömlekçi A.; Tütüncü N.B.; Deyneli O.; Oğuz A.; İlkova H.; Yılmaz T.; Hekimsoy Z.; Ünübol M.; Balcı M.K.; Atmaca A.; Dağdelen S.; Yetkin İ.; Güler S.; Ötünç G.; Özhan L.
    Objective: The aim of the study was to evaluate the effectiveness and safety of insulin glargine 300 U/ mL (Gla-300) in insulin-naive patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drug (OADs) treatment in Turkey. Methods: One hundred eight patients from 20 centers enrolled in the study. Starting from baseline, Gla-300 was self-administered subcutaneously and once daily in the evening. The primary outcome was the mean change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. Results: The mean (±SD) Hb1Ac level of 9.4% (±0.8) at baseline decreased to 7.5% (±0.9) at week 12 (P <.1) and to 7.3% (±0.9) at week 24 (P <.1). Although none of the patients were within the target Hb1Ac level of ≤7% at baseline, the percentage of patients who achieved the target Hb1Ac level was 30.4% at week 12 and increased to 42.9% at week 24. Gla-300 treatment achieved the Hb1Ac target in 21 (19.4%) patients without experiencing a hypoglycemic event and in 27 (25.0%) patients who experienced at least one hypoglycemic event. For each self-monitoring blood glucose time point, significant improvements were observed as compared to baseline (P <.001). Statistically significant improvement (P <.001) was seen in the treatment satisfaction questionnaire – status version scores between baseline and week 24. Conclusion: This study indicated that Gla-300 is effective to provide a successful glycemic control with low risk of hypoglycemia added to OADs in insulin-naive patients with T2DM, and it has the potential to improve the quality of life of patients. © Author(s).